Snowden Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $902K | Sell |
1,718
-213
| -11% | -$112K | 0.03% | 561 |
|
|
2025
Q1 | $1.22M | Buy |
1,931
+314
| +19% | +$199K | 0.04% | 438 |
|
|
2024
Q4 | $1.15M | Buy |
1,617
+108
| +7% | +$76.9K | 0.04% | 460 |
|
|
2024
Q3 | $1.59M | Sell |
1,509
-179
| -11% | -$188K | 0.05% | 380 |
|
|
2024
Q2 | $1.77M | Sell |
1,688
-153
| -8% | -$161K | 0.05% | 355 |
|
|
2024
Q1 | $1.77M | Buy |
1,841
+679
| +58% | +$654K | 0.06% | 347 |
|
|
2023
Q4 | $1.02M | Buy |
1,162
+36
| +3% | +$31.6K | 0.04% | 438 |
|
|
2023
Q3 | $927K | Sell |
1,126
-73
| -6% | -$60.1K | 0.04% | 437 |
|
|
2023
Q2 | $862K | Buy |
1,199
+73
| +6% | +$52.5K | 0.03% | 503 |
|
|
2023
Q1 | $925K | Sell |
1,126
-238
| -17% | -$196K | 0.04% | 476 |
|
|
2022
Q4 | $984K | Sell |
1,364
-94
| -6% | -$67.8K | 0.04% | 452 |
|
|
2022
Q3 | $1M | Sell |
1,458
-167
| -10% | -$115K | 0.05% | 422 |
|
|
2022
Q2 | $960K | Sell |
1,625
-309
| -16% | -$183K | 0.04% | 428 |
|
|
2022
Q1 | $1.35M | Buy |
1,934
+1,175
| +155% | +$820K | 0.05% | 352 |
|
|
2021
Q4 | $479K | Sell |
759
-1,051
| -58% | -$663K | 0.02% | 463 |
|
|
2021
Q3 | $1.1M | Buy |
1,810
+11
| +0.6% | +$6.66K | 0.05% | 352 |
|
|
2021
Q2 | $1M | Buy |
1,799
+314
| +21% | +$175K | 0.05% | 373 |
|
|
2021
Q1 | $703K | Buy |
1,485
+750
| +102% | +$355K | 0.04% | 416 |
|
|
2020
Q4 | $355K | Buy |
735
+222
| +43% | +$107K | 0.02% | 500 |
|
|
2020
Q3 | $287K | Buy |
513
+9
| +2% | +$5.04K | 0.02% | 475 |
|
|
2020
Q2 | $314K | Sell |
504
-22
| -4% | -$13.7K | 0.03% | 455 |
|
|
2020
Q1 | $257K | Buy |
+526
| New | +$257K | 0.03% | 455 |
|
|
2019
Q2 | – | Sell |
-511
| Closed | -$210K | – | 514 |
|
|
2019
Q1 | $210K | Buy |
+511
| New | +$210K | 0.02% | 478 |
|